Save up -80% on Brexpiprazole
|Note: this is a drug discount program, not an insurance plan.|
|RX BIN: 015558||RX PCN: HT||Group ID: DDN6600||Card Holder ID: DDN6600|
|Pharmacists and Patients support.|
2019 Price of Rexulti
|$1,106.72||30 tablets/1 mg|
|price without discount in nearest pharmacy. Price may vary.|
We offer free Brexpiprazole coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your discount card in most local pharmacies to get a discount on Brexpiprazole every time. What are you waiting for? Claim your prescription drug card now!
Get your Prescription
It’s safe and free
Buy drugs in pharmacy
Save money each time
Brexpiprazole volume of distribution
Brexpiprazole reaches peak plasma concentration within 4 hours of administration, and steady state occurs within 10-12 days of dosing. Oral bioavailability is 95%, and can be administered with or without food. Intravenous volume of distribution is 1.56L/kg.
Discount Cards 16,000+
Clients Benefit 29%
Total savings $4,735,080
What is Brexpiprazole
Brexpiprazole is a novel D2 dopamine and serotonin 1A partial agonist, called serotonin-dopamine activity modulator (SDAM), and a potent antagonist of serotonin 2A receptors, noradrenergic alpha 1B and 2C receptors. Brexpiprazole is approved for the treatment of schizophrenia, and as an adjunctive treatment for major depressive disorder (MDD). Although it failed Phase II clinical trials for ADHD, it has been designed to provide improved efficacy and tolerability (e.g., less akathisia, restlessness and/or insomnia) over established adjunctive treatments for major depressive disorder (MDD).
Brexpiprazole mechanism of action
Although the mechanism of action of brexpiprazole in the treatment of MDD and schizophrenia is unclear, the efficacy of brexpiprazole may be attributed to partial agonist activity at serotonin 1A and dopamine D2 receptors, and antagonist activity at serotonin 2A receptors.
Dosage forms of Brexpiprazole
Otsuka America Pharmaceutical, Inc.
Indication of Brexpiprazole
As an adjunctive treatment of major depressive disorder (MDD) and for treatment of schizophrenia.
Toxicity of Brexpiprazole
The most commonly observed adverse effects include: weight increase, akathisia, somnolence, tremor and nasopharyngitis. Neonates are at risk for extrapyramidal and/or withdrawal symptoms if exposed to an antipsychotic drug during the third trimester of development.
RX24 Drugs Disclaimer: before buying a Brexpiprazole on prescription, consult your healthcare provider. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.